BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 25556681)

  • 21. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.
    Colanta A; Lin O; Tafe L; Ghossein R; Nafa K; Mitchell T; Ladanyi M; Arcila M
    Acta Cytol; 2011; 55(6):563-9. PubMed ID: 22156467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity.
    Zoghlami A; Roussel F; Sabourin JC; Kuhn JM; Marie JP; Dehesdin D; Choussy O
    Eur Ann Otorhinolaryngol Head Neck Dis; 2014 Feb; 131(1):7-13. PubMed ID: 23845288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis.
    Marchetti I; Iervasi G; Mazzanti CM; Lessi F; Tomei S; Naccarato AG; Aretini P; Alberti B; Di Coscio G; Bevilacqua G
    Thyroid; 2012 Mar; 22(3):292-8. PubMed ID: 22181337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE; Kim LT; Hackman TG; Dodd LG
    Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
    Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
    Meng Z; Lu J; Wu H; Zhao Y; Luo Y; Gao J; Zhu Q; Jiang Y; Li W; Liang Z
    Tumour Biol; 2016 Jan; 37(1):611-8. PubMed ID: 26240026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF
    Nasirden A; Saito T; Fukumura Y; Hara K; Akaike K; Kurisaki-Arakawa A; Asahina M; Yamashita A; Tomomasa R; Hayashi T; Arakawa A; Yao T
    Virchows Arch; 2016 Dec; 469(6):687-696. PubMed ID: 27718012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DHPLC is a highly sensitive and rapid screening method to detect BRAF(V600E) mutation in papillary thyroid carcinoma.
    Kim TE; Jung ES; Jung CK; Bae JS; Kim SN; Kim GS; Lee HN; Kang CS; Choi YJ
    Exp Mol Pathol; 2013 Feb; 94(1):203-9. PubMed ID: 22691412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.
    Pyo JS; Sohn JH; Kang G
    Endocr Pathol; 2015 Sep; 26(3):211-7. PubMed ID: 25957797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Follicular cell (papillary and follicular) thyroid carcinoma, genetic inheritance, and molecular diagnostic markers].
    Kazubskaia TP; Kozlova VM; Kondrat'eva TT; Pavlovskaia AI; Marakhonov AV; Baranova AV; Ivanova NI; Stepanova AA; Poliakov AV; Belev NF; Brzhezovskiĭ VZh
    Arkh Patol; 2014; 76(5):3-12. PubMed ID: 25543402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma.
    Jing FJ; Liang J; Liang ZY; Meng C; Long W; Li XY; Lin YS
    Chin Med J (Engl); 2013 Aug; 126(16):3013-8. PubMed ID: 23981603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.
    Trovisco V; Soares P; Preto A; de Castro IV; Lima J; Castro P; Máximo V; Botelho T; Moreira S; Meireles AM; Magalhães J; Abrosimov A; Cameselle-Teijeiro J; Sobrinho-Simões M
    Virchows Arch; 2005 Jun; 446(6):589-95. PubMed ID: 15902486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer.
    Beiša A; Beiša V; Stoškus M; Ostanevičiūtė E; Griškevičius L; Strupas K
    Endokrynol Pol; 2016; 67(1):35-40. PubMed ID: 26884113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicentric occurrence of multiple papillary thyroid carcinomas--HUMARA and BRAF mutation analysis.
    Nakazawa T; Kondo T; Tahara I; Kasai K; Inoue T; Oishi N; Mochizuki K; Kubota T; Katoh R
    Cancer Med; 2015 Aug; 4(8):1272-80. PubMed ID: 25882744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.
    Walts AE; Pao A; Sacks W; Bose S
    Hum Pathol; 2014 May; 45(5):935-41. PubMed ID: 24746198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fine-needle aspiration of metastatic papillary thyroid carcinoma found in the liver.
    VandenBussche CJ; Gocke CD; Li QK
    Diagn Cytopathol; 2013 May; 41(5):418-24. PubMed ID: 22362717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomorphological factors and BRAF mutation predicting risk of lymph node metastasis in preoperative liquid-based fine needle aspirations of papillary thyroid carcinoma.
    Chung SY; Lee JS; Lee H; Park SH; Kim SJ; Ryu HS
    Acta Cytol; 2013; 57(3):252-8. PubMed ID: 23636013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.